Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
|ClinicalTrials.gov Identifier: NCT01505699|
Recruitment Status : Completed
First Posted : January 6, 2012
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: RNA analysis Genetic: cytogenetic analysis Genetic: microarray analysis Other: laboratory biomarker analysis|
- To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo.
- To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups.
OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.
|Study Type :||Observational|
|Actual Enrollment :||186 participants|
|Official Title:||Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities|
|Actual Study Start Date :||January 6, 2012|
|Actual Primary Completion Date :||February 6, 2012|
|Actual Study Completion Date :||February 6, 2012|
- Comprehensive view of microRNA expression by cytogenetic subgroup [ Time Frame: 1 year ]
- MicroRNA expression in relation to clinical outcome [ Time Frame: 1 year ]
- Differential microRNA expression between normal B-cells and progenitors compared to B-ALL [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01505699
|Principal Investigator:||Hans-Guido Wendel, MD||Memorial Sloan Kettering Cancer Center|